No Data
Express News | Naya Biosciences Inc - Receives Approval to Initiate NY-303 Clinical Trial in Israel
Express News | Naya Biosciences Announces Initiation of Phase 1/2a Clinical Trial for Its Gpc3-Targeted Nk Engager Bispecific Antibody in Patients With Hepatocellular Carcinoma
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for Its GPC3-targeted NK Engager Bispecific Antibody in Patients With Hepatocellular Carcinoma
Invo BioScience Will Begin Trading Under New Symbol NAYA at Market Open on Oct 22 >INVO
Express News | Naya Biosciences Inc - to Trade Under New Symbol 'naya' From Oct 22
Express News | INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection With Its Recent Merger With Naya Biosciences
No Data
No Data